Applied Therapeutics reports mixed govorestat Phase 2/3 results; CMO departs, Bailey named

Applied Therapeutics, Inc.

INSPIRE trial primary endpoint 10MWRT not met (p=0.7287); stat sig correlation between sorbitol reduction and CMT-HI (p<0.001) and lower limb domain (p=0.038).
Key secondary endpoint CMT-HI showed stat sig improvement at 12 months; sorbitol reduction maintained through 24 months; MRIs suggest slowing of disease progression.
CMO Riccardo Perfetti departed June 15; Evan Bailey appointed CMO. Bailey gets $585k base salary, 300k RSUs vesting over 4 years.
Govorestat generally safe and well tolerated through 24 months; similar adverse event rates between active and placebo groups.

item 5.02item 7.01item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Riccardo Perfetti

Chief Medical Officer

Applied Therapeutics, Inc.

Effective: 2025-06-15
Successor: Evan P. Bailey
Filed: Jun 17, 2025 23:59 UTC

Riccardo Perfetti, M.D., Ph.D., departed his role as Chief Medical Officer, effective as of June 15, 2025.

Appointed

Evan P. Bailey

Chief Medical Officer

Applied Therapeutics, Inc.

Effective: 2025-06-15
Filed: Jun 17, 2025 23:59 UTC

Effective as of June 15, 2025, the Board appointed Evan P. Bailey, the Company’s Senior Vice President, Clinical Development, to succeed Dr. Perfetti as Chief Medical Officer.

Source: SEC EDGAR

accession 0000950170-25-087352

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.